

REMARKS

In view of the restriction requirement dated January 26, 2007, Applicants' elected the product claims, i.e., claims 82-84, in the response filed February 26, 2007. When electing the product claims, Applicants further elected without traverse the 5' translation leader sequence set forth in SEQ ID NO:16, and selected the antibody as the species of polypeptide.

Applicants wish to thank the Examiner for the helpful telephone conversations of March 19 and 20, 2007, wherein the disposition of the product claims was discussed. In view of the election of SEQ ID NO:16 as the translation leader sequence, and selection of the antibody as the species of polypeptide, Applicants have presented new claims 85-96 directed to these elections. Support for these new claims resides throughout the specification and in claims 45, 46, 50, and 67-75, respectively. Claims 82-96 are readable on the elected translation leader and selected species of polypeptide. No new matter is added by way of claim amendment or presentation of new claims.


Claims 44-96 are pending in the application. As no new matter is added by way of claim amendment or presentation of new claims, the Examiner is respectfully requested to enter these amendments into the above-identified application prior to the substantive examination of this application on its merits.

It is not believed that extensions of time or fees for net addition of claims are required, beyond those that may otherwise be provided for in documents accompanying this paper. However, in the event that extensions of time are necessary to allow consideration of this paper, such extensions are hereby petitioned under 37 CFR § 1.136(a), and any fee required therefore

Appl. No.: 10/675,011
Filed: September 30, 2003
Amdt. Dated March 21, 2007

(including fees for net addition of claims) is hereby authorized to be charged to Deposit Account No. 16-0605.

Respectfully submitted,



Leslie T. Henry
Registration No. 45,714

CUSTOMER No. 00826
ALSTON & BIRD LLP
Bank of America Plaza
101 South Tryon Street, Suite 4000
Charlotte, NC 28280-4000
Tel Raleigh Office (919) 862-2200
Fax Raleigh Office (919) 862-2260

ELECTRONICALLY FILED USING THE EFS-WEB ELECTRONIC FILING SYSTEM OF THE UNITED STATES PATENT & TRADEMARK OFFICE ON March 21, 2007.

LEGAL02/30302500v1